Thursday, May 31, 2007
End of the evergreening trend? WSJ blog handicaps Xyzal
Pharmalyst had previously posted about the faltering of some of big pharma's evergreening efforts. Per this post on the WSJ health blog, looks like UCB & Sanofi's Zyrtec to Xyzal switcheroo efforts are likely to stumble.